Use of the 13-valent pneumococcal conjugate vaccine in children and adolescents aged 6 - 17 years.

Use of the 13-valent pneumococcal conjugate vaccine in children and adolescents aged 6 - 17 years.

Item
http://www.wikidata.org/entity/Q38124392
Polysaccharide-specific B cell responses to vaccination in humansSerological response to 13-valent pneumococcal conjugate vaccine in children and adolescents with perinatally acquired HIV infection.Streptococcus pneumoniae colonisation in children and adolescents with asthma: impact of the heptavalent pneumococcal conjugate vaccine and evaluation of potential effect of thirteen-valent pneumococcal conjugate vaccine.Safety and immunogenicity of a new 13-valent pneumococcal conjugate vaccine versus a licensed 7-valent pneumococcal conjugate vaccine: a study protocol of a randomised non-inferiority trial in China.Glycoconjugate vaccines: an update.Background Paper for the update of meningococcal vaccination recommendations in Germany: use of the serogroup B vaccine in persons at increased risk for meningococcal disease.Pneumococcal vaccination in children with underlying conditions.
P2860

Use of the 13-valent pneumococcal conjugate vaccine in children and adolescents aged 6 - 17 years.

Item
http://www.wikidata.org/entity/Q38124392
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Use of the 13-valent pneumococ ...... adolescents aged 6 - 17 years.
@en
type
label
Use of the 13-valent pneumococ ...... adolescents aged 6 - 17 years.
@en
prefLabel
Use of the 13-valent pneumococ ...... adolescents aged 6 - 17 years.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P577
P5875
P698
P921
P356
P1433
P1476
Use of the 13-valent pneumococ ...... adolescents aged 6 - 17 years.
@en
P2093
P2860
P304
P31
P356
10.1517/14712598.2013.824419
P407
P433
P478
P577
P5875
P698
P921